Magnetar Financial’s TG Therapeutics TGTX Stock Holding History

Magnetar Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,617	Closed	-$419K	–	1458
2026 Q1	$419K	Buy	+12,617	New	+$376K	﹤0.01%	669
2024 Q4	–	Sell	-18,259	Closed	-$427K	–	786
2024 Q3	$427K	Sell	18,259 -18,494	-50%	-$404K	0.01%	361
2024 Q2	$654K	Sell	36,753 -15,396	-30%	-$246K	0.01%	311
2024 Q1	$793K	Buy	+52,149	New	+$831K	0.02%	271
2023 Q3	–	Sell	-43,053	Closed	-$1.07M	–	580
2023 Q2	$1.07M	Buy	43,053 +30,358	+239%	+$784K	0.02%	269
2023 Q1	$191K	Buy	+12,695	New	+$193K	﹤0.01%	552
2021 Q3	–	Sell	-5,369	Closed	-$208K	–	1518
2021 Q2	$208K	Buy	+5,369	New	+$211K	﹤0.01%	1102

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Magnetar Financial's TGTX Position: Q2 2026 in Review

Magnetar Financial sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 12,617 shares — an estimated $419K sold.

Magnetar Financial first reported a position in TGTX in Q2 2021 and held it in 7 quarters. The position peaked at $1.07M in Q2 2023. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Magnetar Financial reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
Magnetar Financial sold 12,617 TG Therapeutics shares in Q2 2026, an estimated $419K.
Magnetar Financial first reported a position in TG Therapeutics in Q2 2021 and held it in 7 quarters.
Magnetar Financial's TG Therapeutics position peaked at $1.07M in Q2 2023.
428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.